Company DiaMedica Inc. Toronto S.E.
Stocks
DMA
CA25253T1075
Biotechnology & Medical Research
|
End-of-day quote
Toronto S.E.
|
||
| - CAD | - |
|
| 08-11 | DiaMedica Therapeutics Inc., Q2 2026 Earnings Call, Aug 11, 2026 | |
| 08-10 | DiaMedica Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
Business description: DiaMedica Inc.
Sales by Activity: DiaMedica Inc.
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|
Executive Committee: DiaMedica Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
Rick Pauls
CEO | Chief Executive Officer | 54 | 2009-12-31 |
Scott Kellen
DFI | Director of Finance/CFO | 60 | 2018-03-31 |
Julie Krop
CTO | Chief Tech/Sci/R&D Officer | 60 | 2025-08-10 |
Ambarish Shah
CTO | Chief Tech/Sci/R&D Officer | - | 2023-09-11 |
| Corporate Officer/Principal | - | 2024-02-19 |
Composition of the Board of Directors: DiaMedica Inc.
| Director | Title | Age | Since |
|---|---|---|---|
Michael Giuffre
BRD | Director/Board Member | 70 | 2010-08-09 |
Rick Pauls
CHM | Chairman | 54 | 2008-03-31 |
James Parsons
CHM | Chairman | 60 | 2024-12-31 |
Charles Semba
BRD | Director/Board Member | 66 | 2021-07-14 |
Tanya Lewis
BRD | Director/Board Member | 55 | 2023-02-28 |
Richard Kuntz
BRD | Director/Board Member | 69 | 2023-05-29 |
Daniel O'Connor
BRD | Director/Board Member | 61 | 2025-02-19 |
Company details: DiaMedica Inc.
Bio Therapeutic Drugs
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +4.16% | +3.04% | +49.37% | +94.17% | 74.16B | |
| -3.11% | -3.53% | +21.92% | +74.60% | 57.39B | |
| +0.89% | -0.63% | +4.28% | +34.51% | 47.64B | |
| +0.36% | +0.81% | +352.17% | +689.61% | 44.29B | |
| -0.96% | -4.50% | +26.36% | +33.18% | 42.5B | |
| -0.20% | -0.77% | +3.74% | +100.60% | 40.71B | |
| -0.54% | +2.93% | +9.31% | +50.41% | 30.97B | |
| -2.68% | +2.92% | +29.63% | +19.50% | 28.53B | |
| +0.05% | -1.64% | -7.28% | -14.06% | 24.34B | |
| Average | -0.23% | -0.59% | +54.39% | +120.28% | 43.39B | |
| Weighted average by Cap. | +0.12% | -0.84% | +58.77% | +129.91% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- DMAC Stock
- DMA Stock
- Company DiaMedica Inc.
Select your edition
All financial news and data tailored to specific country editions
